Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer von Lin, J.J., Liu, S.V., McCoach, C.E., Zhu, V.W., Tan, A.C., Yoda, S., Peterson, J., Do, A., Prutisto-Chang, K., Dagogo-Jack, I., Sequist, L.V., Wirth, L.J., Lennerz, J.K., Hata, A.N., Mino-Kenudson, M., Nardi, V., Ou, S.-H.I., Tan, D.S.-W., Gainor, J.F.

Volltext

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry von Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

Volltext

1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours von Drilon, A.E., Lin, J.J., Johnson, M.L., Baik, C.S., Paz-Ares, L.G., Besse, B., Mazieres, J., Swalduz, A., Minchom, A.R., Reuss, J., Gadgeel, S., Riess, J.W., Liu, G., Solomon, B.J., Camidge, D.R., Swe, W., Sun, Y., Shen, J., Zhu, V.W., Felip, E.

Volltext

1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours von Besse, B., Drilon, A.E., Cho, B.C., Camidge, D.R., Neal, J., Lin, C-C., Liu, S.V., Nagasaka, M., Kao, S.C-H., Felip, E., Van Der Wekken, A.J., Lin, C.C., Bauman, J.R., Gadgeel, S., Samant, M., Shen, J., Sun, Y., Zhu, V.W., Upadhyay, V.A., Lin, J.J.

Volltext

Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors von Drilon, A., Besse, B., Camidge, D.R., Ou, S.H.I., Gadgeel, S.M., Johnson, M.L., Calles, A., de Miguel, M.J., Spira, A.I., Felip, E., Lopes, G., van der Wekken, A.J., Elamin, Y.Y., Green, J., Sun, Y., Soglia, J., Zhu, V.W., Lin, J.J.

Volltext

1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI) von McCoach, C., Tan, D.S.W., Besse, B., Goto, K., Zhu, V.W., Rolfo, C.D., Farajian, S., Potter, L., Kherani, J.F., Soldatenkova, V., Olek, E., Lee, P., Park, K.

Volltext

442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) von Keam, B., Hu, M.I., Subbiah, V., Wirth, L., Schuler, M., Mansfield, A.S., Brose, M.S., Curigliano, G., Leboulleux, S., Zhu, V.W., Matos, I., Adkins, D., Baik, C.S., Lopes, G., Godbert, Y., Sarker, D., Zhang, H., Turner, C.D., Taylor, M.H., Lin, C-C.

Volltext

78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study von Besse, B., Johnson, M., Ou, S-H.I., Gadgeel, S., Spira, A., Lin, J., Felip, E., van der Wekken, A.J., Calles, A., de Miguel, M.J., Camidge, D.R., Elamin, Y., Lopes, G.D.L., Liu, S., Bauman, J., Haggstrom, D., Riley, G., Pelish, H.E., Zhu, V.W., Drilon, A.

Volltext

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins) von Riely, G.J., Neal, J.W., Camidge, D.R., Spira, A., Piotrowska, Z., Horn, L., Costa, D.B., Tsao, A., Patel, J., Gadgeel, S., Bazhenova, L., Zhu, V.W., West, H., Mekhail, T., Gentzler, R., Nguyen, D., Bunn, V., Jin, S., Feng, Z., Jänne, P.A.

Volltext

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours... von Liu, S.V., Villaruz, L.C., Lee, V.H.F., Zhu, V.W., Baik, C.S., Sacher, A., McCoach, C.E., Nguyen, D., Li, J.Y-C., Pacheco, J.M., Kim, C., Burns, T.F., Schenk, E.L., Leighl, N., Tozzi, L., Camidge, D.R.

Volltext

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) von Hu, M., Subbiah, V., Wirth, L.J., Schuler, M., Mansfield, A.S., Brose, M.S., Curigliano, G., Leboulleux, S., Zhu, V.W., Keam, B., Matos, I., Lin, C-C., Adkins, D., Baik, C.S., Lopes, G., Godbert, Y., Sarker, D., Zhang, H., Turner, C., Taylor, M.

Volltext

OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations von Bazhenova, L., Chih-Hsin Yang, J., Wang, M., Mitchell, P., Camidge, D. Ross, Fang, J., Nian, W., Chiu, C.-H., Zhou, J., Zhao, Y., Su, W.-C., Yang, T.-Y., Zhu, V.W., Millward, M., Fan, Y., Huang, W.-T., Cheng, Y., Jiang, L., Zheng, L., Janne, P.A.

Volltext

EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study von Drilon, A., Ou, S.-H.I., Gadgeel, S., Johnson, M., Spira, A., Lopes, G., Besse, B., Felip, E., van der Wekken, A.J., Calles, A., de Miguel, M.J., Camidge, D.R., Elamin, Y., Liu, S., Bauman, J., Haggstrom, D., Riley, G., Pelish, H.E., Zhu, V.W., Lin, J.J.

Volltext

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCL... von Lee, D.H., Subbiah, V., Gainor, J.F., Taylor, M.H., Zhu, V.W., Doebele, R.C., Lopes, G., Baik, C., Garralda, E., Gadgeel, S.M., Kim, D.-W., Turner, C.D., Palmer, M., Miller, S., Curigliano, G.

Volltext

The allure of ‘ALUR’ von Nagasaka, M., Zhu, V.W., Ou, S.-H.I.

Volltext

Acquired Resistance to KRASG12C Inhibition in Cancer von Awad, Mark M, Liu, Shengwu, Rybkin, Igor I, Arbour, Kathryn C, Dilly, Julien, Zhu, Viola W, Johnson, Melissa L, Heist, Rebecca S, Patil, Tejas, Riely, Gregory J, Jacobson, Joseph O, Yang, Xiaoping, Persky, Nicole S, Root, David E, Lowder, Kristen E, Feng, Hanrong, Zhang, Shannon S, Haigis, Kevin M, Hung, Yin P, Sholl, Lynette M, Wolpin, Brian M, Wiese, Julie, Christiansen, Jason, Lee, Jessica, Schrock, Alexa B, Lim, Lee P, Garg, Kavita, Li, Mark, Engstrom, Lars D, Waters, Laura, Lawson, J. David, Olson, Peter, Lito, Piro, Ou, Sai-Hong I, Christensen, James G, Jänne, Pasi A, Aguirre, Andrew J

Volltext

Effects of the Crystalline Structure on the Switching Field and Its Distribution of Bit Patterned Co/Pt Multilayer Media von Guo, V.W., Hwan-Soo Lee, Yi Luo, Moneck, M.T., Jian-Gang Zhu

Volltext

AB0441 Bone geometry, density and microarchitecture: Relationship between peripheral and periarticular skeletal site assessed by high resolution peripheral quantitative computed to... von Zhu, Y., Li, E.K., Hung, V.W., Qin, L., Tam, L.-S.

Volltext

THU0083 Abnormal volumetric density and microarchitecture at the radius in chinese female patients with rheumatoid arthritis: A case-control study von Zhu, Y., Li, E.K., Hung, V.W., Leung, P.-C., Kwok, A.W., Qin, L., Tam, L.-S.

Volltext

FRI0324 Dkk-1 and rankl/opg predict changes in bone mineral density and bone microstructure in sle on long-term glucocorticoid: a prospective study von Tang, X. L., Griffith, J. F., Qin, L., Wong, C.-K., Hung, V. W., Zhu, T. Y., Leung, P.-C., Li, E. K., Tam, L.-S.

Volltext